Stay updated with breaking news from Michaelb Atkins. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ASCO 2024, advanced clear cell renal cell carcinoma (ccRCC), Belzutifan, LITESPARK-013 Study, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).
Researchers continue to investigate novel immunotherapy drugs for the treatment of renal cell carcinoma.
Further understanding of the cancer immunity cycle could drive the development of novel immune therapies for patients with renal cell carcinoma.
WATERTOWN, Mass., Sept. 11, 2023 -- Werewolf Therapeutics, Inc. , an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate...
Michael B. Atkins, MD, discusses the rationale for launching the phase 2 HCRN GU16-260 trial in patients with advanced renal cell carcinoma.